RxDoctor Payments Data

Ankit Patel, MD

Internal Medicine · Chelmsford, MANPI 1083096317

Payments from drug & device makers

$23,338in general payments, 2019–2025

Across 64 payments — averaging $364.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acadia Pharmaceuticals Inc$23K
  • Otsuka America Pharmaceutical, Inc.$197
  • Vifor Pharma, Inc.$70
  • AbbVie$35
  • Exact Sciences$28
  • Astellas Pharma US Inc$24
  • plus $19 from 1 others

What the payments were for

  • Consulting fees$3001%
  • Speaking & faculty fees$20,13486%
  • Travel & lodging$7393%
  • Food & beverage$2,1659%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,338 in reported general payments places this provider in the 95th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$258,355
Medicare patients
693
Services billed
1,876

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban724$137,871
NuplazidPimavanserin Tartrate20$40,952
TrulicityDulaglutide52$39,266
XareltoRivaroxaban151$33,281
OzempicSemaglutide13$13,273
Divalproex Sodium255$11,195
LinzessLinaclotide15$10,952
JardianceEmpagliflozin50$10,190
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$9,709
Atorvastatin Calcium1,121$9,473
MyrbetriqMirabegron60$8,926
Breo ElliptaFluticasone/Vilanterol19$8,570
SantylCollagenase Clostridium Hist.14$8,038
Mirtazapine390$7,576
Chlorpromazine Hcl20$7,466

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$22,966$40,95220 claims
AbbVieLinzess, Vraylar, Creon$35$21,71343 claims
Astellas Pharma US IncMyrbetriq$24$8,92660 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Chelmsford

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →